Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Jana Nekvindova"'
Publikováno v:
Journal of Fungi, Vol 7, Iss 6, p 438 (2021)
The genera Menisporopsis, Multiguttulispora and Tainosphaeria (Chaetosphaeriaceae) are saprobes inhabiting decaying plant material. This study is based on an integrated morpho-molecular characterisation to assess their generic concepts and explore ph
Externí odkaz:
https://doaj.org/article/ade10f15f8c8428dae1686126ce2fc0e
Autor:
Martina Réblová, Miroslav Kolařík, Jana Nekvindová, Andrew N. Miller, Margarita Hernández-Restrepo
Publikováno v:
Microorganisms, Vol 9, Iss 4, p 706 (2021)
Zanclospora (Chaetosphaeriaceae) is a neglected, phialidic dematiaceous hyphomycete with striking phenotypic heterogeneity among its species. Little is known about its global biogeography due to its extreme scarcity and lack of records verified by mo
Externí odkaz:
https://doaj.org/article/d5d57739158e4f6b885f1f0fc935ba68
Autor:
Tomas Smutny, Jan Dusek, Lucie Hyrsova, Jana Nekvindova, Alzbeta Horvatova, Stanislav Micuda, Sabine Gerbal-Chaloin, Petr Pavek
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 10, Iss 1, Pp 136-152 (2020)
Pregnane X receptor (PXR) is the major regulator of xenobiotic metabolism. PXR itself is controlled by various signaling molecules including glucocorticoids. Moreover, negative feed-back regulation has been proposed at the transcriptional level. We e
Externí odkaz:
https://doaj.org/article/104e530f438645bb88ef9570631024be
Autor:
Lenka Besse, Lenka Sedlarikova, Fedor Kryukov, Jana Nekvindova, Lenka Radova, Ondrej Slaby, Petr Kuglik, Martina Almasi, Miroslav Penka, Marta Krejci, Zdenek Adam, Ludek Pour, Sabina Sevcikova, Roman Hajek
Publikováno v:
PLoS ONE, Vol 10, Iss 9, p e0137294 (2015)
Poor outcome of extramedullary disease in multiple myeloma patients and lack of outcome predictors prompt continued search for new markers of the disease. In this report, we show circulating microRNA distinguishing multiple myeloma patients with extr
Externí odkaz:
https://doaj.org/article/1c18f8435a574f45a2322070f78e88ad
Autor:
Marian Kacerovsky, Filip Vrbacky, Radka Kutova, Lenka Pliskova, Ctirad Andrys, Ivana Musilova, Ramkumar Menon, Ronald Lamont, Jana Nekvindova
Publikováno v:
PLoS ONE, Vol 10, Iss 5, p e0126884 (2015)
To analyze the cervical microbiota in women with preterm prelabor rupture of membranes (PPROM) by pyrosequencing and to document associations between cervical microbiota, cervical inflammatory response, microbial invasion of the amniotic cavity (MIAC
Externí odkaz:
https://doaj.org/article/3722fc6c6097469e935a047cf1ecaa7c
Autor:
Lenka Kubiczkova, Fedor Kryukov, Ondrej Slaby, Elena Dementyeva, Jiri Jarkovsky, Jana Nekvindova, Lenka Radova, Henrieta Greslikova, Petr Kuglik, Eva Vetesnikova, Ludek Pour, Zdenek Adam, Sabina Sevcikova, Roman Hajek
Publikováno v:
Haematologica, Vol 99, Iss 3 (2014)
Multiple myeloma still remains incurable in the majority of cases prompting a further search for new and better prognostic markers. Emerging evidence has suggested that circulating microRNAs can serve as minimally invasive biomarkers for multiple mye
Externí odkaz:
https://doaj.org/article/8f3f68e7ced84c7bb0ffbab5100aec83
Autor:
Rudolf, Kukla, Radka, Bolehovska, Jakub, Radocha, Lenka, Pliskova, Pavel, Zak, Filip, Vrbacky, Jana, Nekvindova, Helena, Zemlickova
Publikováno v:
The new microbiologica. 43(2)
The aim of this study was to test the detection performance of the cpsA, lytA and ply genes through qPCR in the identification of Streptococcus pneumoniae in respiratory tract samples. Specificity was tested on a panel of 128 streptococci and other b
Publikováno v:
American Journal of Hematology
Autor:
Lenka, Kubiczkova Besse, Lenka, Sedlarikova, Fedor, Kryukov, Jana, Nekvindova, Lenka, Radova, Martina, Almasi, Jana, Pelcova, Jiri, Minarik, Tomas, Pika, Zuzana, Pikalova, Vlastimil, Scudla, Marta, Krejci, Zdenek, Adam, Ludek, Pour, Roman, Hajek, Sabina, Sevcikova
Publikováno v:
American journal of hematology. 90(3)
Publikováno v:
Clinical and experimental rheumatology. 33(3)
Leflunomide (LEF) is a disease-modifying anti-rheumatic drug used for treating rheumatoid arthritis (RA). More than 50% of patients are withdrawn from LEF treatment within one year, mainly due to AEs. Importantly, it is not possible to predict which